

February 17, 2020

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Norio Hamada, Chairman of the Board and Chief Executive Officer (CEO), Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Marketing Approvals for 3 Ingredients / 8 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 3 ingredients / 8 products of generic drugs today on February 17, 2020 as below.

Products list approved for marketing

Classes	Product Name	Original Brand Name
Cholesterol absorption inhibitor from small intestine Therapeutic agent for hyperlipemia	Ezetimibe Tablets 10mg “KMP”	Zetia Tablets 10mg
Extended-release selective histamine H1 antagonist / therapeutic agent for allergic disease	Levocetirizine hydrochloride Tablets 5mg “KMP”	Xyzal Tablets 5mg
NMDA receptor antagonist Therapeutic agent for Alzheimer dementia	Memantine hydrochloride Tablets 5mg/10mg/20mg “KMP”	MEMARY TABLETS 5mg/10mg/20mg
	Memantine hydrochloride OD Tablets 5mg/10mg/20mg “KMP”	MEMARY OD TABLETS 5mg/10mg/20mg